Shaveta Vinayak, MD
Half of patients with metastatic triple-negative breast cancer (TNBC) achieved disease control when treated with the combination of a poly (ADP-ribose) polymerase (PARP) inhibitor and an anti–PD-1 agent, a preliminary prospective study showed.
The most frequent AEs (all grades, all 55 patients) were nausea (55%), fatigue (42%), anemia (31%), thrombocytopenia (24%), and constipation (20%). Grade ≥3 AEs consisted of anemia (15%), thrombocytopenia (13%), and fatigue (7%).
Vinayak S, Tolaney SM, Schwartzberg LS, et al. TOPACIO/Keynote-162: niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. J Clin Oncol. 2018;36(suppl; abstr 1011). abstracts.asco.org/214/AbstView_214_213387.html.
... to read the full story